Barinthus Biotherapeutics plc
BRNS
$0.74
-$0.02-2.49%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -41.77M | -52.31M | -66.43M | -75.88M | -69.43M |
| Total Depreciation and Amortization | 886.00K | 1.87M | 2.85M | 3.16M | 3.74M |
| Total Amortization of Deferred Charges | 2.60M | 2.80M | 3.00M | 3.20M | 3.20M |
| Total Other Non-Cash Items | 7.10M | 9.21M | 12.96M | 27.51M | 26.84M |
| Change in Net Operating Assets | 4.75M | 2.00M | -359.00K | 11.36M | -2.48M |
| Cash from Operations | -26.43M | -36.44M | -47.98M | -30.65M | -38.12M |
| Capital Expenditure | 0.00 | -32.00K | -37.00K | -315.00K | -429.00K |
| Sale of Property, Plant, and Equipment | 569.00K | 508.00K | 453.00K | 451.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 569.00K | 476.00K | 416.00K | 136.00K | -429.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 0.00 | 2.00K | 839.00K | 1.30M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00 | 0.00 | 2.00K | 839.00K | 1.30M |
| Foreign Exchange rate Adjustments | -2.30M | 2.58M | 7.01M | -752.00K | 7.26M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -28.15M | -33.39M | -40.55M | -30.43M | -29.99M |